NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
TrumpTariffTradeLaunchAnnouncePricesStrikesMajorFebruaryChinaMarketCourtNewsDigestSundayTimelineHongKongServiceMilitaryTechSafetyGlobalOil
TrumpTariffTradeLaunchAnnouncePricesStrikesMajorFebruaryChinaMarketCourtNewsDigestSundayTimelineHongKongServiceMilitaryTechSafetyGlobalOil
All Articles
STAT News
Clustered Story
Published 5 days ago

STAT+: Psilocybin data could be good enough for approval

STAT News · Feb 17, 2026 · Collected from RSS

Summary

And other biotech news brought to you by The Readout newsletter

Full Article

And other biotech news brought to you by The Readout newsletter Adobe Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good day! Today: A look at growing GLP-1 competition in China, a drug reviewed as part of the FDA’s shiny new fast-track voucher hits a roadblock, and Secretary Kennedy’s vaccine overhaul gets a hard look in federal court. Also, psilocybin may be headed for approval despite mildly anticlimactic remission rates, and Ocular’s wet AMD drug does .… fine. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Share this story
Read Original at STAT News

Related Articles

scientificamerican.com1 day ago
FDA wants to make more drugs available over the counter , but experts have raised safety concerns

Published: 20260220T234500Z

STAT News2 days ago
STAT+: Pharmalittle: We’re reading about an FDA official’s speech, a Grail cancer blood test, and much more

The FDA's top drug regulator indicated in her first address to staff that she will scrutinize antidepressants and shots used to protect babies from RSV

STAT News3 days ago
STAT+: Pharmalittle: We’re reading about the FDA pushing OTC meds, its new trial standards, and much more

FDA Commissioner Marty Makary said he believes “everything should be over the counter” unless a drug is unsafe, addictive or requires monitoring

insidermonkey.com4 days ago
Analysts Bullish on COMPASS Pathways plc ( CMPS ) Following Psychedelics Symposium and Model Updates

Published: 20260219T033000Z

STAT News4 days ago
STAT+: Investors cheer Compass’ psilocybin data

And other biotech news brought to you by The Readout

STAT News5 days ago
STAT+: Pharmalittle: We’re reading about China’s homegrown GLP-1 drugs, a puzzling FDA rejection, and more

The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program to fast-track drug reviews